View in EDS HTML Full Text PDF Full Text

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

Saved in:
Bibliographic Details
Title: Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
Authors: Panse J; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.; Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany., Han B; Department of Hematology, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking, People's Republic of China., Cermak J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Gonzalez Fernandez FA; Hematology Service, Hospital Clínico San Carlos, Madrid, Spain., Gotoh A; Department of Hematology, Tokyo Medical University, Tokyo, Japan., Kulasekararaj AG; Department of Haematological Medicine, King's College Hospital, London, UK.; National Institute for Health Research and Wellcome King's Clinical Research Facility and King's College London, London, UK., Kyselova O; Medical Center 'Ok!Clinic+' of International Institute of Clinical Research LLC, Kyiv, Ukraine.; Institute of Hematology and Transfusiology, National Academy of Medical Science, Kyiv, Ukraine., Sahin F; Department of Hematology, Ege University, Izmir, Turkey., Scheinberg P; Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil., Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen und University Hospital Ulm, Ulm, Germany., Straetmans N; Department of Haematology, University Hospital Saint-Luc, Brussels, Belgium., Ueda Y; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Suita, Japan., Chang AC; Genentech, Inc., South San Francisco, CA, USA., Gentile B; Genentech, Inc., South San Francisco, CA, USA. bgentile@gmail.com., Stefani J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Uguen M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Röth A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Source: Annals of hematology [Ann Hematol] 2025 Jun; Vol. 104 (6), pp. 3199-3212. Date of Electronic Publication: 2025 Jun 14.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40515823
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Panse+J%22">Panse J</searchLink>; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.; Centre for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany.<br /><searchLink fieldCode="AU" term="%22Han+B%22">Han B</searchLink>; Department of Hematology, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Cermak+J%22">Cermak J</searchLink>; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Gonzalez+Fernandez+FA%22">Gonzalez Fernandez FA</searchLink>; Hematology Service, Hospital Clínico San Carlos, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gotoh+A%22">Gotoh A</searchLink>; Department of Hematology, Tokyo Medical University, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Kulasekararaj+AG%22">Kulasekararaj AG</searchLink>; Department of Haematological Medicine, King's College Hospital, London, UK.; National Institute for Health Research and Wellcome King's Clinical Research Facility and King's College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Kyselova+O%22">Kyselova O</searchLink>; Medical Center 'Ok!Clinic+' of International Institute of Clinical Research LLC, Kyiv, Ukraine.; Institute of Hematology and Transfusiology, National Academy of Medical Science, Kyiv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Sahin+F%22">Sahin F</searchLink>; Department of Hematology, Ege University, Izmir, Turkey.<br /><searchLink fieldCode="AU" term="%22Scheinberg+P%22">Scheinberg P</searchLink>; Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Schrezenmeier+H%22">Schrezenmeier H</searchLink>; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute of Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen und University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Straetmans+N%22">Straetmans N</searchLink>; Department of Haematology, University Hospital Saint-Luc, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Ueda+Y%22">Ueda Y</searchLink>; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Suita, Japan.<br /><searchLink fieldCode="AU" term="%22Chang+AC%22">Chang AC</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Gentile+B%22">Gentile B</searchLink>; Genentech, Inc., South San Francisco, CA, USA. bgentile@gmail.com.<br /><searchLink fieldCode="AU" term="%22Stefani+J%22">Stefani J</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Uguen+M%22">Uguen M</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Röth+A%22">Röth A</searchLink>; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229107334%22">Annals of hematology</searchLink> [Ann Hematol] 2025 Jun; Vol. 104 (6), pp. 3199-3212. <i>Date of Electronic Publication: </i>2025 Jun 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9107334 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0584 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209395555%22">09395555 </searchLink><i>NLM ISO Abbreviation: </i>Ann Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40515823
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00277-025-06449-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3199
    Titles:
      – TitleFull: Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Panse J
      – PersonEntity:
          Name:
            NameFull: Han B
      – PersonEntity:
          Name:
            NameFull: Cermak J
      – PersonEntity:
          Name:
            NameFull: Gonzalez Fernandez FA
      – PersonEntity:
          Name:
            NameFull: Gotoh A
      – PersonEntity:
          Name:
            NameFull: Kulasekararaj AG
      – PersonEntity:
          Name:
            NameFull: Kyselova O
      – PersonEntity:
          Name:
            NameFull: Sahin F
      – PersonEntity:
          Name:
            NameFull: Scheinberg P
      – PersonEntity:
          Name:
            NameFull: Schrezenmeier H
      – PersonEntity:
          Name:
            NameFull: Straetmans N
      – PersonEntity:
          Name:
            NameFull: Ueda Y
      – PersonEntity:
          Name:
            NameFull: Chang AC
      – PersonEntity:
          Name:
            NameFull: Gentile B
      – PersonEntity:
          Name:
            NameFull: Stefani J
      – PersonEntity:
          Name:
            NameFull: Uguen M
      – PersonEntity:
          Name:
            NameFull: Röth A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2025 Jun
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0584
          Numbering:
            – Type: volume
              Value: 104
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Annals of hematology
              Type: main
ResultId 1